Effective October 26, 2009 Urigen Pharmaceuticals, Inc. (the "Company") entered into Debt Settlement Agreements with William J, Garner, its CEO, and KTEC Holdings, Inc. ("KTEC"). Also, effective October 27, 2009, the Company entered into a Debt Settlement Agreement with C. Lowell Parsons, a director of the Company. Pursuant to the terms of the Debt Settlement Agreements, Messrs. Parsons and Garner and KTEC converted outstanding amounts plus accrued interest owed to them into shares of common stock of the Company at a rate of $0.10 per share. Pursuant to the Debt Settlement Agreements the Company agreed to issue shares of its common stock as follows:

1. 292,562 shares to William J. Garner,
2. 4,888,862 shares to C. Lowell Parsons, and
3. 1,284,441 shares to KTEC.

Item 9.01           Financial Statements and Exhibits

Exhibit Number   Description


                     10.1 Form of Debt Settlement Agreement